Amgen Jumps as Migraine Drug Wows in Late-Stage Study Post author:Sam Post published:January 22, 2018 Post category:BioPharma Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies. Source: BioSpace You Might Also Like Takeda CEO Actively Hunts for Deals, Looks to Shed Non-Core Businesses November 16, 2017 5 Massachusetts Biotechs That Tanked More Than 60% in 2017 January 1, 2018 SoCal's Evolus Files for $75M IPO January 8, 2018